SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

Key Points

• Short interest surged in SOPHiA GENETICS during June, rising 141.3% to 636,132 shares as of June 30. That represents about 0.8% of the float, with a short-interest ratio of 1.4 days.
• Several insiders sold shares recently, including CEO Jurgi Camblong and insider Philippe Menu. Insiders sold 184,243 shares worth about $987,562 over the last quarter, though the transactions were made under pre-arranged 10b5-1 plans.
• The stock was down 1.1% to $5.66, while the company’s latest earnings showed an EPS loss that missed expectations even as revenue came in above estimates. Analysts currently have a consensus Hold rating with an average price target of $7.50.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 636,132 shares, an increase of 141.3% from the June 15th total of 263,601 shares. Based on an average daily volume of 459,329 shares, the short-interest ratio is presently 1.4 days. Currently, 0.8% of the company's stock are sold short.

Insider Buying and Selling

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 50,069 shares of the business's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the sale, the chief executive officer owned 3,601,493 shares in the company, valued at approximately $20,888,659.40. The trade was a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 7,393 shares of the company's stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.16, for a total transaction of $38,147.88. Following the transaction, the insider owned 233,387 shares in the company, valued at approximately $1,204,276.92. The trade was a 3.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 184,243 shares of company stock worth $987,562 over the last quarter. Corporate insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at about $49,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Stock Down 1.1%

NASDAQ SOPH traded down $0.06 on Tuesday, reaching $5.66. The company had a trading volume of 13,763 shares, compared to its average volume of 189,605. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The company's fifty day moving average is $5.18 and its 200 day moving average is $4.99. SOPHiA GENETICS has a 52-week low of $2.92 and a 52-week high of $6.30. The stock has a market capitalization of $474.48 million, a P/E ratio of -10.85 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analysts' expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Wall Street Analyst Weigh In

SOPH has been the topic of several recent research reports. BTIG Research reaffirmed a "buy" rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.